Fig. 1

Fli1 heterozygous deficiency suppresses the activity of ALDH in CD103⁻CD11b⁻ dermal DCs in BLM-treated mice. Wild-type (WT) and Fli1^+/− mice were treated with bleomycin (BLM) for a week. a Representative flow cytometry plots of ALDH staining in CD11c⁺ cells from the dermis of BLM-treated WT and Fli1^+/− mice are shown (left panels). The result in the presence of the ALDH inhibitor diethylaminobenzaldehyde (DEAB) is shown as control. The proportions of CD11c⁺ cells positive for ALDH are summarized in a right graph (n = 6–7 per group). b Representative flow cytometry plots of CD11b and CD103 staining in ALDH-producing CD11c⁺ cells from the dermis of BLM-treated WT and Fli1^+/− mice are shown (n = 6–7 per group). c Mean fluorescence intensity (MFI) of ALDH was examined in CD11b⁻CD103⁻ DCs isolated from the dermis. Each graph indicates mean ± SEM of the indicated parameters. * P < 0.05; ** P < 0.01